HG202 is the first-ever clinical-stage CRISPR/Cas13 RNA-editing and the only clinical-stage RNA-targeting therapy for nAMD. “This open IND for HG202 by the US FDA – the first regulator to have cleared ...

Synthetic genes, though few, can generate complex biomolecular materials when their expression is part of a temporal control ...

Nate Russart, a Fargo scientist, ran his first New York City Marathon, inspired by the life-saving CAR T-cell therapy he ...

Researchers uncover a link between impaired glutathione–ascorbate metabolism and early dopamine increases in Huntington's ...

NAT is an emerging field of medicine that uses nucleic acids such as DNA and RNA to treat a range of diseases, including cancer and viral infections. Covid-19 vaccines based on mRNA technology, which ...

DelveInsight's 'Exosomes Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and ...

If approved, donidalorsen would be a first-in-class RNA-targeted medicine for hereditary angioedema. The agency’s goal date ...

Neuroblastoma (NB), the most prevalent extracranial solid tumor in children, poses a significant therapeutic challenge due to ...

CET/CEST The issuer is solely responsible for the content of this announcement. CureVac to Present at the 12th Interna ...

CureVac Strengthens Leadership Team with Appointment of Seasoned industry Executive Axel Sven Malkomes as Chief financial Officer ...

Researchers have developed synthetic genes that function like the genes in living cells. The artificial genes can build intracellular structures through a cascading sequence that builds ...

Researchers identified 16 distinct types of nerve cells involved in human touch and compared them with those in mice and ...